© 2019 Sun Ophthalmics, a division of Sun Pharmaceutical Industries, Inc. All rights reserved.
CEQUA and NCELL are trademarks of Sun Pharma Global FZE.
PM
-
US
-
CQA
-
0328 10/2019
References: 1. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2018. 2. Data on le.
Cranbury, NJ: Sun Pharmaceutical Industries, Inc. 3. US Patent 9,937,225 B2. 4. Tauber J, Schechter BA, Bacharach J,
et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and ef cacy of
OTX
-
101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921
-
1929.
Use with Contact Lenses: CEQUA should not be administered while wearing
contact lenses. If contact lenses are worn, they should be removed prior to
administration of the solution. Lenses may be reinserted 15 minutes following
administration of CEQUA ophthalmic solution.
ADVERSE REACTIONS
The most common adverse reactions reported in greater than 5% of patients
were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other
adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation,
headache, and urinary tract infection.
Please see brief summary of Full Prescribing Information on the adjacent page.
